Evidence map›Paper›PMID 26538631›Full record

Trial reportJournal of the American Society of Nephrology : JASN2016

Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial.

Nisha Bansal, Myra A Carpenter, Daniel E Weiner, Andrew S Levey, Marc Pfeffer, John W Kusek, Jianwen Cai, Lawrence G Hunsicker, Meyeon Park, Michael Bennett and 2 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Trial
  4. Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Trial
  5. Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017
    Trial
  6. Review
  7. Plasma NGAL levels in stable kidney transplant recipients and the risk of allograft loss.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Article
  8. Article
  9. Review
  10. Urinary liver-type fatty acid-binding protein is independently associated with graft failure in outpatient kidney transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021
    Article
  11. Article
  12. Role of novel biomarkers in kidney transplantation.World journal of transplantation · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Nisha BansalKidney Research Institute, Division of Nephrology, University of Washington, Seattle, Washington; nbansal@nephrology.washington.edu.
Myra A CarpenterDepartment of Biostatistics, University of North Carolina, Chapel Hill, North Carolina;
Daniel E WeinerDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts;
Andrew S LeveyDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts;
Marc PfefferDivision of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts;
John W KusekNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland;
Jianwen CaiDepartment of Biostatistics, University of North Carolina, Chapel Hill, North Carolina;
Lawrence G HunsickerCollege of Medicine, Department of Medicine, University of Iowa, Iowa City, Iowa;
Meyeon ParkDivision of Nephrology, University of California, San Francisco, California; and.
Michael BennettDepartment of Pediatrics, Cincinnati Children's Hospital, Cincinnati, Ohio.
Kathleen D LiuDivision of Nephrology, University of California, San Francisco, California; and.
Chi-Yuan HsuDivision of Nephrology, University of California, San Francisco, California; and.
University of California, San Francisco · USTufts Medical Center · USUniversity of North Carolina at Chapel Hill · USBrigham and Women's Hospital · USCincinnati Children's Hospital Medical Center · USNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Iowa · USUniversity of Washington · US

Funding

Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) TrialU01DK061700 · NIDDK · TUFTS MEDICAL CENTER · PI LEVEY, ANDREW S · 2001 to 2011
$29.0M
"Validation of Novel CKD Biomarkers in CRIC"U01DK085649 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN, LIU, KATHLEEN D · 2009 to 2013
$4.4M
Patient Oriented Research in Kidney DiseaseK24DK092291 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 2011 to 2020
$1.2M
Blood Pressure in Advanced Chronic Kidney DiseaseK23DK088865 · NIDDK · UNIVERSITY OF WASHINGTON · PI BANSAL, NISHA · 2010 to 2014
$848k
NIDDK NIH HHS K23 DK088865NIDDK NIH HHS K24 DK092291NIDDK NIH HHS U01 DK061700NIDDK NIH HHS U01 DK085649
6 · The paper itself

Abstract

Recipients of kidney transplants (KTR) are at increased risk for cardiovascular events, graft failure, and death. It is unknown whether urine kidney injury biomarkers are associated with poor outcomes among KTRs. We conducted a post hoc analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial using a case-cohort study design, selecting participants with adjudicated cardiovascular events, graft failure, or death. Urine neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), IL-18, and liver-type fatty acid binding protein (L-FABP) were measured in spot urine samples and standardized to urine creatinine concentration. We adjusted for demographics, cardiovascular risk factors, eGFR, and urine albumin-to-creatinine ratio. Patients had 291 cardiovascular events, 257 graft failure events, and 359 deaths. Each log increase in urine NGAL/creatinine independently associated with a 24% greater risk of cardiovascular events (adjusted hazard ratio [aHR], 1.24; 95% confidence interval [95% CI], 1.06 to 1.45), a 40% greater risk of graft failure (aHR, 1.40; 95% CI, 1.16 to 1.68), and a 44% greater risk of death (aHR, 1.44; 95% CI, 1.26 to 1.65). Urine KIM-1/creatinine and IL-18/creatinine independently associated with greater risk of death (aHR, 1.29; 95% CI, 1.03 to 1.61 and aHR, 1.25; 95% CI, 1.04 to 1.49 per log increase, respectively) but not with risk of cardiovascular events or graft failure. Urine L-FABP did not associate with any study outcomes. In conclusion, among prevalent KTRs, higher urine NGAL, KIM-1, and IL-18 levels independently and differentially associated with greater risk of adverse outcomes.

Indexed as

Kidney TransplantationBiomarkersCardiovascular DiseasesCohort StudiesDouble-Blind MethodFemaleFolic AcidHumansMaleMiddle AgedPostoperative ComplicationsRisk FactorsBiomarkersFolic Acidcardiovascular diseasekidney transplantationmortality

Identifiers

PMID26538631
PMCPMC4926968
OpenAlexW2173037816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.